Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma - Top-Institutions - MDSpire

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

  • By

  • Ming Yao

  • Xavier Cheng-Hong Tsai

  • Chung-Wu Lin

  • Shu-Lang Liao

  • Cheng-Ping Wang

  • Wei-Li Ma

  • Yi-Hsuan Wei

  • Hsiao-Wei Lee

  • Jyh-Ming Liou

  • Wei-Li Chen

  • I-Jong Wang

  • Ann-Lii Cheng

  • Sung-Hsin Kuo

  • May 29, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    National Taiwan University Hospital
    National Taiwan University Hospital

    Taipei, Taiwan

    Key Differentiators

    • Gastroenterology

  • #2

    Nippon Kokan Fukuyama Hospital
    Nippon Kokan Fukuyama Hospital

    Fukuyama, Japan

    Key Differentiators

    • Gastroenterology

  • #3

    Henan Cancer Hospital
    Henan Cancer Hospital

    Zhengzhou, China

    Key Differentiators

    • Oncology
    • Gastroenterology

  • #4

    Osaka City University Hospital
    Osaka City University Hospital

    Osaka, Japan

    Key Differentiators

    • Gastroenterology

  • #5

    Hiroshima University Hospital
    Hiroshima University Hospital

    Hiroshima, Japan

    Key Differentiators

    • Gastroenterology

Original Source(s)

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

  • by Ming Yao, Xavier Cheng-Hong Tsai, Chung-Wu Lin, Shu-Lang Liao, Cheng-Ping Wang, Wei-Li Ma, Yi-Hsuan Wei, Hsiao-Wei Lee, Jyh-Ming Liou, Wei-Li Chen, I-Jong Wang, Ann-Lii Cheng, Sung-Hsin Kuo

  • May 29, 2026

Related Content

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

MRI perfusion in evaluating ovarian masses: diagnostic performance of wash out rate